/Investor DB

Sante Ventures — 2022 Investments

2 investments dated 2022 · listed companies and verified rows first · show all

Reimagine Carereimaginecare.cominSeries A · Jan 2022 · $25M

Reimagine Care partners with cancer providers and health systems to deliver virtual oncology care combining AI-powered support, clinical expertise, and digital monitoring to manage symptoms, reduce emergency visits, and improve patient outcomes outside the clinic setting.

AI & Machine LearningDigital HealthHealthtechNashville, US

Dan Nardi(Mr. Nardi is the CEO and a director of the Issuer)Keith Figlioli(Director)Feby Abraham(Director)Chris Stenzel(Director)

BoardDouglas French(Director)Harlan Levine(Director)in

Co-investorsCU Healthcare Innovation FundFirst Trust Capital PartnersLRVHealthMartin VenturesMcKesson VenturesOncology Ventures

Sensorium Therapeuticssensorium.bioinSeries A · Oct 2022 · $30M

Sensorium Therapeutics is a clinical-stage biotech company developing novel CNS therapies for anxiety, epilepsy, and cognitive dysfunction using its SensAI platform, which integrates AI, chemistry, and curated natural product data to identify therapeutic patterns from over 50 million biological relationships.

AI & Machine LearningBiotechDigital HealthMedford, US

Jerrold Rosenbaum(Co-Founder & Chair Emeritus, Massachusetts General Hospital (MGH) Department of Psychiatry)inJacob Hooker(Co-Founder & Chief Executive Officer)inPranav Tadi(Executive Officer)Stephen Haggarty, PhD(Co-Founder & Professor of Neurology, Harvard Medical School)Dick Simon, MBA(Co-Founder)

BoardRyan Katz(Director)in

Co-investorsBonaventure Equity, LLCCU Healthcare Innovation FundDolby Family VenturesHatteras Venture PartnersIter InvestmentsMission Biocapital+5 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.